AIM
ADVM

Alambic Investment Management’s Adverum Biotechnologies ADVM Stock Holding History

Alambic Investment Management’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-5,041
Closed -$292K – 350
2018
Q1 		$292K Buy
+5,041
New +$314K 0.04% 372

Other funds holding ADVM

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Alambic Investment Management's ADVM Position: Q2 2018 in Review

Alambic Investment Management sold out of Adverum Biotechnologies (ADVM) in Q2 2018, closing a stake of 5,041 shares — an estimated $292K sold.

Alambic Investment Management first reported a position in ADVM in Q1 2018 and held it in 1 quarter. The position peaked at $292K in Q1 2018. 100 funds tracked by Wall St. Rank hold ADVM as of Q2 2018.

  • Alambic Investment Management reported no remaining Adverum Biotechnologies position as of Q2 2018 after selling out during the quarter.
  • Alambic Investment Management sold 5,041 Adverum Biotechnologies shares in Q2 2018, an estimated $292K.
  • Alambic Investment Management first reported a position in Adverum Biotechnologies in Q1 2018 and held it in 1 quarter.
  • Alambic Investment Management's Adverum Biotechnologies position peaked at $292K in Q1 2018.
  • 100 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2018.

Based on Alambic Investment Management's 13F filing for Q2 2018, filed 14 Aug 2018.